BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results.
Q4 2024 Earnings Call Transcript February 19, 2025 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $0.64, expectations were $0.54. Operator: Ladies and gentlemen, thank you ...
A single gene in the shorebird species known as ruffs controls the levels of testosterone in males, and this in turn affects ...
A team of Chinese scientists has used targeted gene editing to develop rice that produces coenzyme Q10 (CoQ10), a vital ...
A virus originally found in animals, mpox -- which causes the disease of the same name -- is now circulating in humans. Since 2022, it has been the cause of major epidemics spreading outside endemic ...
We view Avita’s RECELL system as a sound alternative treatment for large second- and third-degree burns treated in burn centers. It compares favorably on price and ease of use with new products and ...
A virus originally found in animals, mpox – which causes the disease of the same name – is now circulating in humans.
Researchers found that high fructose intake, especially from processed foods, is linked to metabolic dysfunction-associated ...
Since the erythrocyte assay was performed approximately six weeks after transfusion therapy, the low enzyme activity of 118 units presumably was the result of normal red-cell aging in vivo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback